ArticleScientific reports2025
CircRNA ZFR promotes cell progression by regulating miR-96a-5p/SLC1A1 axis in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CircZFR functions in cancer from molecular networks to precision therapy.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research has identified the dysregulation of circular RNA ZFR (circRNA ZFR) as a key factor in hepatocellular carcinoma (HCC) progression, though its precise molecular mechanisms remain unclear. This study assessed circRNA ZFR expression in clinical samples and HCC cells using qRT-PCR and Fluorescent In Situ Hybridization assays. Cell functions were evaluated through colony formation, transwell, and wound healing assays. circRNA ZFR and miR-96a-5p interaction was investigated using luciferase reporter assays and qRT-PCR, while miR-96a-5p and SLC1A1 interaction was examined using luciferase reporter assays, western blot analysis, and Chromatin Isolation by RNA Purification/Mass Spectrometry (CHIRP/MS). CircRNA ZFR was significantly upregulated in blood, tissue samples and HCC cells compared to their respective normal controls (P < 0.001), and were associated with tumor differentiation (r = 0.249, p = 0.031), tumor size (r = 0.258, p = 0.027) and tumor-node-metastasis (TNM) stage (r = 0.287, p = 0.020). CircRNA ZFR overexpression promoted HCC cell proliferation, migration and invasion while its knockdown inhibited HCC progression. miR-96a-5p was identified as the putative target for CircRNA ZFR and its inhibition promoted HCC through modulating the expression of SLC1A1 gene. Collectively, circRNA ZFR knockdown retarded HCC progression by sponging miR-96a-5p and modulating SLC1A1 expression, suggesting that the circZFR/miR-96a-5p/SLC1A1 axis may serve as potential therapeutic targets for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.